Acivery has developed a new process for the production of pharmaceutical actives for pulmonary drug. Our technology leads to the precipitation of non-agglomerated crystalline powders with narrow particle size distributions
In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine
Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.
In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.
| Activery at the annual Generics conference |
|
THE 11th ANNUAL IGPA CONFERENCE
A GLOBAL MARKET - A GLOBAL INDUSTRY
8 - 10 December 2008
Organised by the Members of IGPA:
CGPA | EGA | GPhA | IPA | JGA
Pre-conference Seminar:
US GENERICS FROM DIFFERENT INDUSTRY PERSPECTIVES
8 December 2008
Organised by Greenblum & Bernstein
INTERCONTINENTAL HOTEL | GENEVA | SWITZERLAND
CONFERENCE TOPICS
Key Developments in Intellectual Property Affecting Access to Generic Medicines
* Patent Linkage. Comparing different applications of “patent linkage” and how these affect access to generic medicines
* Data Exclusivity vs Data Protection (Article 39.3 TRIPS): understanding the differences between these concepts and their impact on generic competition in developing countries
* Intellectual property enforcement measures: when legitimate measures to protect innovation can be misused as barriers to generic competition
Developments in Generic Medicines Markets Worldwide: Asia and India
* Impact of changes in regulatory infrastructure on the healthcare industry in India
* Have recent government polices to stimulate the uptake of generic medicines in Japan been successful?
* What has been the impact of rapid economic change in China on the local generic medicines market?
Developments in Generic Medicines Markets Worldwide: Europe and North America
* Current developments in the USA impacting the generic medicines industry
* Threats and opportunities in a rapidly changing European generics market
* Changes in government reimbursement for generic medicines: A Canadian case study
Developments in Generic Medicines Markets Worldwide
* How have regulatory and IP developments affected the development of the generic markets in the other regions of the world?
Market Dynamics
* Overview of the global generic pharmaceutical market
* Key market dynamics for the generic medicines industry: strategic developments
Regulatory Developments Impacting on the Business of Generic Medicines Companies
* WHO prequalification of medicines programme: opportunities for generic medicines manufacturers
* GMP/GCP/GLP inspections developments
* ICH Quality Topics Q8, Q9, Q10: new opportunities for generic manufacturers?
* New developments in the use of TRIPS flexibilities for fostering the production of essential medicines / Case Study: The German government’s programme on TRIPS and pharmaceutical production in developing countries
CEO Panel
CONFIRMED SPEAKERS
Pascal Lamy, Director General, World Trade Organization (WTO) | Greg Perry, Director General, European Generic medicines Association (EGA) | Yehudah Livneh, Chairman of IGPA IP Committee | Michelle Childs, Head of European Affairs, Knowledge Ecology International (KEI) | Christoph Spennemann, Legal expert, United Nations Conference on Trade and Development (UNCTAD) | Julia Pike, Intellectual Property Director & Counsel, Hospira Global Pharma R&D | Roger Kampf, Counsellor, Intellectual Property Division, WTO | German Velasquez, Director, WHO Secretariat on Public Health, Innovation and Intellectual Property | Dilip Shah, Secretary-General, Indian Pharmaceutical Alliance (IPA) | Surinder Singh, Drugs Controller General, Indian Government | Kenichi Nagano, Director General, Japan Generic medicines Association (JGA) | Mandy Chui, Country Principal China Consulting & Services, IMS Health | Kathleen Jaeger, President & CEO, Generic Pharmaceutical Association (GPhA) | Eric Gorka, President, European Generic medicines Association (EGA) | Allan Oberman, Chairman, Canadian Generic Pharmaceutical Association (CGPA) | Jim Keon, President, Canadian Generic Pharmaceutical Association (CGPA) | Lina Owais, Deputy General Director, Jordanian Assoc. of Pharma. Manufacturers (JAPM) | Skhumbuzo G. Ngozwana, Chairman, National Association of Pharmaceutical Manufacturers (NAPM) | Odnir Finotti, Vice President, Pró Genéricos (Brazil) | Alan Sheppard, Global Head Generics, IMS Health | Vijay P. Karwal, Managing Director, Healthcare Banking Group, The Royal Bank of Scotland (RBS) | Nicholas Cappuccino, Chairman of IGPA Science Committee | Lembit Rägo, Head of WHO Quality Assurance & Safety: Medicines Unit, Department of Medicines Policy and Standards | Frank Schmiedchen, Governmental Director IP Rights, Federal Ministry for Economic Cooperation & Development of Germany | Andreas Rummelt, CEO, Sandoz | Pankaj Patel, CEO, Cadila Healthcare | Francis Gurry, Director General of the World Intellectual Property Organization (WIPO)
NETWORKING EVENTS
Welcome Cocktail
Welcome Coffees & Coffee Breaks
Networking Buffet Lunches
Cocktail & Conference Dinner
End-of-Conference Farewell Drinks
PLATINUM SPONSOR
Barr Pharmaceuticals
SEMINAR SPONSOR
Greenblum & Bernstein
EVENT SPONSOR
IMS Health
SILVER SPONSOR
Winston & Strawn LLP
|